lixisenatide + alpha-glucosidase inhibitor

This is a **combination drug** consisting of **lixisenatide**, a glucagon-like peptide-1 receptor agonist, and an **alpha-glucosidase inhibitor**, commonly represented by medications such as acarbose, miglitol, or voglibose. Lixisenatide enhances glucose-dependent insulin secretion and suppresses glucagon release, slows gastric emptying, and reduces food intake. Alpha-glucosidase inhibitors act locally in the intestine to block the breakdown of complex carbohydrates, thereby reducing the absorption of glucose and postprandial blood glucose spikes. Used together, this combination targets multiple mechanisms for glycemic control in type 2 diabetes, improving both fasting and postprandial glucose levels[1][4][5][3].